Mycophenolate Risk Mitigation

CE / CME

Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour of which 1.00 are eligible for pharmacology credit

Released: February 25, 2025

Expiration: May 29, 2025

Activity

Progress
1 2
Course Completed

References

  1. Mycophenolate mofetil [prescribing information]. South San Francisco, CA: Genentech USA; 2022.
  2. Mycophenolic acid [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2022.
  3. Bandeira M, Vieira A, Guimarã V, et al. Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases. Clin Exp Rheumatol. 2022;40(suppl 134):32-39.
  4. US Food and Drug Administration. Pregnancy and lactation labeling (drugs) final rule. fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule. Accessed February 20, 2025.
  5. Leek JC, Arif H. Pregnancy medications. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025.
  6. Coscia LA, Armenti DP, King RW, et al. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet. 2015;4:42-55.
  7. Mycophenolate REMS Program. mycophenolaterems.com. Accessed February 20, 2025.
  8. Armenti VT, Daller JA, Constantinescu S, et al. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Clin Transpl. 2006;57-70.
  9. King RW, Baca MJ, Armenti VT, et al. Pregnancy outcomes related to mycophenolate exposure in female kidney transplant recipients. Am J Transplant. 2017;17:151-160.
  10. Perez-Aytes A, Marin-Reina P, Boso V, et al. Mycophenolate mofetil embryopathy: a newly recognized teratogenic syndrome. Eur J Med Genet. 2017;60:16-21.
  11. Centers for Disease Control and Prevention. Cleft lip and palate. cdc.gov/ncbddd/birthdefects/cleftlip.html. Accessed February 20, 2025.
  12. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375:555-562.
  13. Shen J, Che Y, Showell E, et al. Interventions for emergency contraception. Cochrane Database Syst Rev. 2019;1:CD001324.
  14. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84:363-367.
  15. Cleland K, Zhu H, Goldstuck N, et al. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27:1994-2000.
  16. Turok DK, Gero A, Simmons RG, et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med. 2021;384:335-344.
  17. Turok DK, Godfrey EM, Wojdyla D, et al. Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod. 2013;28:2672-2676.
  18. Thompson I, Sanders JN, Schwarz EB, et al. Copper intrauterine device placement 6-14 days after unprotected sex. Contraception. 2019;100:219-221.
  19. Boraas CM, Sanders JN, Schwarz EB, et al. Risk of pregnancy with levonorgestrel-releasing intrauterine system placement 6-14 days after unprotected sexual intercourse. Obstet Gynecol. 2021;137:623-625.
  20. US Food and Drug Administration. Mycophenolate single shared system REMS. OB/GYN Contraception Counseling Letter. fda.gov/media/86233/download. Accessed February 20, 2025.
  21. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020;72:529-556.
  22. The American College of Obstetricians and Gynecologists. Immune modulating therapies in pregnancy and lactation. Committee Opinion number 776. acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/04/immune-modulating-therapies-in-pregnancy-and-lactation. Accessed February 20, 2025